Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase. by Cagin, Umut et al.
Original ArticleRescue of Advanced Pompe Disease
in Mice with Hepatic Expression
of Secretable Acid a-Glucosidase
Umut Cagin,1 Francesco Puzzo,1,2 Manuel Jose Gomez,3 Maryse Moya-Nilges,4 Pauline Sellier,1 Catalina Abad,5
Laetitia Van Wittenberghe,1 Nathalie Daniele,1 Nicolas Guerchet,1 Bernard Gjata,1 Fanny Collaud,1
Severine Charles,1 Marcelo Simon Sola,1 Olivier Boyer,5 Jacomina Krijnse-Locker,4 Giuseppe Ronzitti,1
Pasqualina Colella,1 and Federico Mingozzi1,2,6
1INTEGRARE, Genethon, INSERM, Université d’Evry, Université Paris-Saclay, 91002 Evry, France; 2Sorbonne Université, Paris, France; 3Bioinformatics Unit, Centro
Nacional de Investigaciones Cardiovasculares Carlos III, 28029 Madrid, Spain; 4Pasteur Institute, Rue du Dr. Roux, 75015 Paris, France; 5Université de Rouen
Normandie–IRIB, 76183 Rouen, France; 6Spark Therapeutics, Philadelphia, PA 19103, USAReceived 13 November 2019; accepted 26 May 2020;
https://doi.org/10.1016/j.ymthe.2020.05.025.
Correspondence: Federico Mingozzi, PhD, Spark Therapeutics, Philadelphia, PA
19103, USA.
E-mail: federico.mingozzi@sparktx.comPompe disease is a neuromuscular disorder caused by disease-
associated variants in the gene encoding for the lysosomal
enzyme acid a-glucosidase (GAA), which converts lysosomal
glycogen to glucose. We previously reported full rescue of
Pompe disease in symptomatic 4-month-old Gaa knockout
(Gaa/)mice by adeno-associated virus (AAV) vector-mediated
liver gene transfer of an engineered secretable form of GAA (sec-
GAA). Here, we showed that hepatic expression of secGAA res-
cues the phenotype of 4-month-old Gaa/ mice at vector doses
at which the native form of GAA has little to no therapeutic ef-
fect. Based on these results, we then treated severely affected 9-
month-old Gaa/mice with an AAV vector expressing secGAA
and followed the animals for 9 months thereafter. AAV-treated
Gaa/mice showed complete reversal of the Pompe phenotype,
with rescue of glycogen accumulation in most tissues, including
the central nervous system, and normalization of muscle
strength. Transcriptomic profiling of skeletal muscle showed
rescue of most altered pathways, including those involved in
mitochondrial defects, a finding supported by structural and
biochemical analyses, which also showed restoration of lyso-
somal function. Together, these results provide insight into
the reversibility of advanced Pompe disease in the Gaa/mouse
model via liver gene transfer of secGAA.
INTRODUCTION
Glycogen storage disease type II, also known as Pompe disease (PD), is
an autosomal recessive disorder caused bymutations in the enzymeacid
a-glucosidase (GAA) gene, which encodes for the lysosomal enzyme
acid GAA.1 This enzyme converts glycogen into glucose within lyso-
somes, and its deficiency leads to the accumulation of the substrate in
virtually all of the tissues of the body.2 Infantile-onset PD (IOPD) is
the most severe form of PD, characterized by cardiomegaly, respiratory
failure, muscle weakness, and cognitive impairment.3 IOPD subjects
show absent or barely detectable residual GAA activity and, in the
absence of any treatment, die within the first years of life.4 On the other2056 Molecular Therapy Vol. 28 No 9 September 2020 ª 2020 The Au
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GAA activity and usually present a milder phenotype with progressive
respiratory and muscle impairments with no signs of cardiac defects.1,5
Nowadays, the only approved treatment for PD is enzyme replacement
therapy (ERT), based on high doses of recombinant human GAA
(rhGAA), infused intravenously weekly in classic infantile patients
and 2 two weeks in LOPD patients.6 ERT relies on a cross-correction
mechanism by which circulating rhGAA binds to the mannose-6-
phosphate receptors (MPRs) on the cell surface and trafficked to the
lysosome.1 However, despite having a major impact on the course of
the disease in both IOPD and LOPD patients, ERT presents important
shortcomings due to the short half-life in plasma of rhGAA and its
inability to cross the blood-brain barrier (BBB), resulting in limited ef-
ficacy in skeletal muscle and brain.3,7 Low expression of MPRs and the
autophagy block in skeletal muscle are also among the factors limiting
ERT efficacy.1,8 Finally, rhGAA exhibits high immunogenicity, partic-
ularly in IOPD patients, with consequent development of neutralizing
antibodies that can reduce significantly the efficacy of ERT.9
Likely due to these limitations, emerging clinical data appear to indi-
cate that ERT has more of a stabilizing effect on LOPD patients who
generally experience improvements of muscle and respiratory func-
tion only during the first months after initiation.10,11 Similarly, early
intervention with ERT appears to be crucial for a positive treatment
outcome in IOPD patients,12 possibly highlighting the inability of
the current treatment to reverse PD.
Development of gene therapy approaches may be a promising alter-
native to ERT for the treatment of PD. Adeno-associated virusthors.
tp://creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.org(AAV) vectors have been proven as a safe and promising platform for
in vivo gene transfer in humans, as demonstrated in numerous clin-
ical trials.13–20 In the context of PD, one reported trial was carried
out in pediatric subjects by intra-diaphragmatic injection of an
AAV1 encoding the human GAA transgene.21 The procedure was
demonstrated safe with evidence of increase in respiratory
function.21,22
Several preclinical studies of gene therapy have been published (re-
viewed in Ronzitti et al.23) using a well-established Gaa knockout
mousemodel (Gaa/ hereafter).24,25 Among these studies, we recently
showed full correction of PD in symptomatic 4-month-old Gaa/
mice with AAV vector-mediated liver gene transfer of an engineered
secretable GAA (secGAA) transgene. The high and stable circulating
GAA plasma activity levels achieved with secGAA rescued muscle
and central nervous system (CNS) pathology without development
of humoral immune responses to the engineered transgene.26 However,
questions about the approach remain, including the long-term efficacy
of secGAA at limiting vector doses and its ability to correct PD in
severely affected mice. Published studies suggest that rescue of
advanced PD in mice with gene transfer is challenging, as an only par-
tial amelioration of the disease phenotype was observed even at rela-
tively high vector doses.27,28 One possible explanation of these findings
relies on the impairment of lysosomal function characteristic of PD. Ly-
sosomes play a key role in regulating many cellular processes, and
recent studies showed significant mitochondrial defects in Pompe skel-
etal muscle, which have been associated with autophagic block,29–31
and may explain why advanced PD is poorly reversible.
Here, we first performed a study in 4-month-old Gaa/ mice to
demonstrate that secGAA can drive enhanced therapeutic efficacy
and survival compared to the native version of the transgene following
long-term hepatic gene transfer with low doses of AAV8 vectors. Next,
given the superior efficacy of secGAA compared to its native form, we
tested the reversibility of the PD phenotype by treating 9-month-old
Gaa/ mice with advanced disease by liver gene transfer with an
AAV8-secGAA vector. AAV8-secGAA-mediated gene transfer re-
sulted in high and sustained circulating plasma activity of GAA, driving
body-wide rescue of glycogen accumulation and normalization ofmus-
cle function. Further investigation of muscle ultrastructure by electron
microscopy (EM) revealed that pathological features were partially cor-
rected by AAV8-secGAA treatment. RNA sequencing revealed
normalization of expression levels of a majority of genes involved in
bioenergetics homeostasis, along with partial normalization of a large
part of transcriptomics alterations associated with PD. This correlated
with functional, biochemical, and structural findings, suggesting that
liver gene therapy with secGAA could potentially represent an efficient
therapeutic strategy for the treatment at advanced stages of PD.
RESULTS
Liver Expression of Secretable GAA Rescues PD at Low Vector
Doses
We previously showed that liver-targeted expression of secGAA
via AAV8 vectors drives superior therapeutic efficacy comparedto the native version of the enzyme.26 However, long-term
follow-up (10 months post-treatment) of animals injected with
relatively high vector doses (2  1012 vector genome [vg]/kg)
showed no clear difference between treatment groups.26 To
compare more carefully the therapeutic efficacy of secGAA with
that of the native form of the enzyme (GAAco), we injected
4-month-old Gaa/ mice at a dose of 5  1011 vg/kg and followed
the animals for 10 months (Figure 1A). At this limiting vector
dose, GAAco failed to extend the lifespan of animals, whereas sec-
GAA-treated animals had identical survival to wild-type (Gaa+/+)
littermates (Figure 1B). Accordingly, secGAA expression in
liver fully rescued (FR) cardiomegaly (Figure 1C) and muscle
strength (Figure 1D). Conversely, liver expression of GAAco did
not affect cardiomegaly (Figure 1C) and only partially rescued
(PR) muscle strength (Figure 1D). We next looked at tissue
GAA enzymatic activity and glycogen content. GAA activity (Fig-
ure 1E) and glycogen content (Figure 1F) in the diaphragm of
animals treated with the secGAA or GAAco transgenes did not
differ significantly. Similar results were observed in triceps (Fig-
ures S1A and S1B) and heart (Figures S1C and S1D). The lack
of statistical significance between secGAA and GAAco cohorts
was likely due to the low number of animals surviving to the
end of the study in the GAAco cohort. A limited effect was
observed in the brain of secGAA-treated animals (Figures S1E
and S1F), whereas no effect was observed in the spinal cord of an-
imals from either secGAA or GAAco cohorts (Figures S1G and
S1H). Vector genome copy number in liver was not different
across cohorts of treated animals, confirming the equivalent effi-
ciency of liver transduction of the vectors used in the study (Fig-
ure S1I). These findings confirm that, at limiting vector doses, sec-
GAA drives superior rescue of survival and muscle strength
compared to GAAco in Gaa/ mice.
Hepatic Expression of secGAA Results in Correction of Muscle
Phenotype in Gaa–/– Mice with Advanced Disease
Previous reports of liver gene transfer with AAV vectors express-
ing native forms of GAA showed only marginal rescue of estab-
lished PD phenotype in Gaa/ mice.27,28,32 Based on the results
obtained (Figure 1), we therefore wanted to test whether secGAA
expression could provide therapeutic benefit in Gaa/ mice with
advanced disease. We first measured the amount of glycogen in
various tissues of naive Gaa/ and Gaa+/+ mice at 4, 9, and
14 months of age. Gaa/ mice showed greater glycogen accumu-
lation compared to Gaa+/+ mice in all tissues (Figures S2A–S2D),
with significantly higher amounts of glycogen measured at
9 months in triceps, brain, and diaphragm (Figures S2A–
S2C). Lower glycogen content was observed in the tissues of
14-month-old Gaa/ mice (Figures S2A–S2D), consistent with
previous findings in Pompe mice.33 Survival of Gaa/ mice was
less than 50% at 14 months of age (Figure S2E). Grip-test measure-
ment showed a significant decrease in Gaa/ mice (Figure S2F),
with loss of muscle strength slightly more pronounced at 9 and
14 months (average 32%) compared to 4 months (average
26%) (Figure S2F).Molecular Therapy Vol. 28 No 9 September 2020 2057
Figure 1. Liver Expression of Secretable GAA
Rescues Pompe Disease at Low Vector Doses
(A–F) 4-month-old Gaa/ mice were injected with an
AAV8-GAAco (GAAco-Gaa/) or AAV8-secGAA (sec-
GAA-Gaa/) vector at a dose of 5  1011 vg/kg. Gaa+/+
(PBS-Gaa+/+) and Gaa/ (PBS-Gaa/) mice injected with
PBS served as controls in the study. Animals were followed
for 10 months after treatment (n = 7/8 per cohort). (A)
Graphical representation of the study design (m.o., months
old). (B) Survival curve. The numbers in parentheses show
the number of animals survived at the end of the study. (C)
Hypertrophy of cardiac muscle, reported as heart weight
percentage of body mass. (D) Muscle strength tested by
grip test at 3, 6, and 9 months post-treatment, presented
as percentage of PBS-Gaa+/+. (E and F) GAA enzymatic
activity (E) and glycogen content (F) in diaphragm. Statis-
tical analyses: (B) Kaplan-Meier log rank test. *p < 0.05;
(C, E, and F) one-way ANOVA with Tukey’s post hoc.
ns, not significant. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001; (D) two-way ANOVA time per
treatment. +p < 0.05; **, ++, or ##p < 0.01; +++p <
0.001; ++++ or ****p < 0.0001. In all graphs, error bars
represent the standard deviation of the mean.
Molecular TherapyBased on this natural history study, we intravenously injected
9-month-old Gaa/ mice with an AAV8-secGAA vector at a
dose of 2  1012 vg/kg (Figure 2A). PBS-treated, age-matched
Gaa/ and Gaa+/+ male mice were used as the control in all of
the experiments. Liver-mediated gene transfer of secGAA in
Gaa/ mice resulted in high and stable enzyme activity in plasma
throughout the 9 months of follow-up (Figure 2B). This resulted in
detection of supraphysiologic enzyme activity in muscle (Fig-
ure 2C) and liver (Figure S3A). Muscle uptake of secGAA resulted
in the complete clearance of glycogen in heart, diaphragm, and tri-
ceps (Figures 2D and S3B).
In agreement with the correction of the disease phenotype at
the biochemical level, we observed the normalization of cardiome-
galy and body weight (Figures 2E and S3C) in AAV8-
secGAA-treated animals to an extent undistinguishable from
PBS-Gaa+/+ mice. Mice were also subjected to grip test to
assess muscle strength before AAV vector injection and at 4, 6,
and 9 months thereafter (Figure 2F). Gaa/ mice treated with
the AAV8-secGAA vector showed a steady increase in muscle
strength over time, achieving full recovery by the end of the
study (Figure 2F). Improvement in muscle strength was
accompanied by a normalization of the skeletal muscle weight
(Figure S3D), whereas a significant loss of weight in triceps and2058 Molecular Therapy Vol. 28 No 9 September 2020gastrocnemii was detected in PBS-treated
Gaa/ mice (Figure S3D).
Plethysmography measurement of respiratory
function34 did not show any significant differ-
ence among treatment cohorts, due to the low
number of mice in each group, although a ten-dency to improve tidal volume was noted in Gaa/ mice treated
with the AAV8-secGAA vector (Figure 2G). Altogether, these results
highlight rescue of advancedmuscle pathology at the biochemical and
functional level in Gaa/ mice upon AAV8-secGAA treatment.
secGAA Partially Corrects Glycogen Accumulation in the CNS of
18-Month-Old Gaa–/– Mice
We next measured GAA enzymatic activity in the CNS of mice, spe-
cifically in the brain and spinal cord (Figure 3). Although detectable,
significant, lower enzyme activity was found in Gaa/ mice treated
with the AAV8-secGAA vector compared to PBS-treated Gaa+/+
mice (Figure 3A). The residual GAA activity detected was reflected
in the partial correction of glycogen content in brain and spinal
cord (about 30% lower than the PBS-Gaa/ cohort) (Figure 3B).
Western blot analysis of brain and spinal cord (Figures 3C and 3D)
allowed detection of the precursor (110-kDa) and lysosomal (76-
kDa) forms of human GAA in Gaa/ mice injected with the
AAV8-secGAA vector, documenting the presence of functionally
active GAA in the lysosomes in the CNS. Finally, representative his-
tological sections of the brain (Figure 3E) stained with periodic acid-
Schiff (PAS) confirmed the partial reduction of glycogen content in
the brain of AAV8-secGAA-treated Gaa/ mice. Together, these re-
sults confirm that sustained levels of circulating GAA can, at least
partially, ameliorate the CNS pathology in Gaa/ mice.
www.moleculartherapy.orgHepatic Expression of secGAA Restores Muscle Structure and
Lysosomal Function in Old Gaa–/– Mice
In order to assess reversal ofmuscle pathology at the structural level, we
carried out hematoxylin and eosin (H&E) staining and EM analysis on
muscle sections. Histological sections revealed structural abnormalities
in affected Gaa/ mice treated with PBS, whereas wild-type litter-
mates (Gaa+/+) and secGAA-treated Gaa/ mice had similar muscle
structure (Figure 4A). Quantification of p62, Lamp1, Beclin1, and
LC3b, known markers of lysosomal homeostasis and autophagic
buildup in PD,35–37 showed significant phenotype reversal in sec-
GAA-treated animals for most markers analyzed (Figures 4B–4H).
High-resolution EM also revealed the presence of enlarged lysosomes
throughout the muscle of Gaa/ mice (Figure 4I). Quantification of
EM findings showed widespread presence of enlarged lysosomes in
PBS-treated Gaa/ mice, which were undetectable in wild-type ani-
mals (Figure 4I). Significantly smaller lysosomes (75% of reduction
compared to PBS-treated Gaa/ mice) were observed in AAV8-sec-
GAA vector-treated Gaa/ mice (Figure 4J).
Alterations of lysosomal function have been associated with mitochon-
drial defects in the skeletal muscle of Gaa/ mice.30,31 EM analysis of
skeletal muscle showed the expected ultrastructure with mitochondria
homogenously distributed along the muscle fibers in Gaa+/+ mice (Fig-
ure 5A). Muscle from the PBS-Gaa/ cohort exhibited areas of clus-
tering of mitochondria and glycogen-filled lysosomes, which were less
evident in Gaa/ mice treated with the AAV8-secGAA vector (Fig-
ure 5A).Western blot analysis was then performed to assess mitochon-
drial content using the three known mitochondrial markers: CoxIV (a
subunit of complex IV), ATP-b (beta subunit of complex V), and
SDHA (succinate dehydrogenaseA, a subunit of complex II). This anal-
ysis showed that PBS-treated Gaa/ mice had a slight but not statisti-
cally significant increase in the amounts of CoxIV compared to Gaa/
mice treatedwithAAV8-secGAAandGaa+/+mice (Figures 5B and 5C).
Significantly higher amounts of both ATP-b (Figures 5D and 5E) and
SDHA (Figures 5F and 5G) were detected in Gaa/ mice compared
to both AAV8-secGAA-treated Gaa/ mice and wild-type littermates
(PBS-Gaa+/+) (Figures 5E and 5G).
These results demonstrate that hepatic expression of secGAA can
normalize autophagy, lysosome size, and mitochondrial content.
Liver-Targeted Expression of secGAA Largely Normalizes the
Transcriptome in Skeletal Muscle
In order to better understand the molecular signatures of diseased
muscle in advanced PD and analyze the effect of AAV8-secGAA at
the molecular level, we performed transcriptome profiling by RNA
sequencing using quadriceps of animals at the end of the study
(18 months of age, 9 month postvector infusion). Principal-compo-
nent analysis (PCA) revealed that the global transcriptome of sec-
GAA-treated animals was intermediate between wild-type littermates
(PBS-Gaa+/+) and untreated Gaa/ animals (PBS-Gaa/) (Fig-
ure S4A). Differential expression analysis was then performed to
identify subsets of genes with significant expression changes across
the experimental groups. Pairwise comparative analysis yielded inthe highest number of differentially expressed genes (DEGs) between
PBS-treated Gaa+/+ and PBS-treated Gaa/ animals (2,802 DEGs)
(Figure S4B). AAV8-secGAA-treated Gaa/ mice displayed a lower
number of DEGs when compared to Gaa/ and Gaa+/+ animals–434
and 371, respectively (Figure S4B). The decrease in DEGs in secGAA-
Gaa/ versus PBS-Gaa+/+ mice, as compared to PBS-Gaa/ versus
PBS-Gaa+/+, is in agreement with the functional and biochemical data
(Figures 2, 4, and 5) and is consistent with a phenotype of secGAA-
Gaa/mice intermediate between PBS-Gaa+/+ and PBS-Gaa/. Hi-
erarchical clustering using the expression profile confirmed that mus-
cle from AAV8-secGAA-treated Gaa/ animals was more similar to
PBS-treated Gaa+/+ animals than to PBS-treated, affected Gaa/ an-
imals (Figure S4C). Functional enrichment analysis performed with
Ingenuity Pathway Analysis (IPA) on the list of DEGs (2,802 genes
from the comparison of PBS-Gaa/ versus PBS-Gaa+/+) identified
257 upstream transcription factors (TFs), including nuclear factor
kB (NF-kB), signal transducer and activator of transcription 1
(STAT1), and RELA Proto-Oncogene (REL-A) (Figure S5A). These
TFs, which are mainly involved in inflammatory responses and in
the muscle tissue homeostasis pathways,38–41 were found to be highly
activated in Gaa/ animals (Figures S5A and S5B).
After having identified genes with altered expression in the Gaa/
background (relative to Gaa+/+), we focused on those for which expres-
sion had been restored to wild-type levels upon liver-targeted expres-
sion of secGAA. For this purpose, we grouped the complete collection
of genes detected as differentially expressed in any of the three compar-
isons (Figure S4B) into six clusters using k-means. Each cluster con-
tained around 450 genes with similar expression profiles. We grouped
clusters with complementary profiles into three metaclusters that rep-
resented genes with different degrees of normalized expression toward
Gaa+/+ (wild-type) levels: full, partial, or no rescue (Figure 6A). After
AAV8-secGAA treatment, gene expression was either partially or fully
normalized in approximately 75% of the identified DEGs, whereas the
expression of 25% of the DEGs was not rescued (NR). Functional
enrichment analysis with IPA indicated that metaclusters containing
genes with FR or PR expression levels were associated to pathways
involved in bioenergetics homeostasis, such as sirtuin signaling, mito-
chondrial dysfunction, and integrin signaling (Figure 6B). Pathways
related to glucose metabolism (i.e., glycolysis I, gluconeogenesis I,
glycogen degradation II, and glycogen degradation III) were also asso-
ciated to metaclusters with FR or PR expression levels after hepatic
expression of secGAA (Figure S6).
As defects in muscle regeneration have been recently documented in
Gaa/ mice,33,42 we analyzed the expression pattern of several genes
of interest. We observed partial normalization of the expression levels
of genes involved in muscle regeneration and plasticity, such as
Capn3,Myoz1, andDysf43–45 (Figure S7). Interestingly, the expression
level of the dystrophin gene (Dmd), a key gene for structure and func-
tion of muscle cells, in which mutations can result in Duchenne and
Becker muscular dystrophy, was normalized46 (Figure S7). Along the
same line, we also evaluated fibrosis in muscle. At the histological
level, sirius red staining showed limited changes in signal intensityMolecular Therapy Vol. 28 No 9 September 2020 2059
Figure 2. secGAA Normalizes Muscle Phenotype in Advanced Stages of Pompe Disease
(A–G) 9-month-old mice were injected with an AAV8-secGAA (secGAA-Gaa/) vector at a dose of 2  1012 vg/kg. Gaa+/+ (PBS-Gaa+/+) and Gaa/ (PBS-Gaa/) mice
injected with PBS served as controls in the study. Animals were followed for 9 months after treatment (n = 3/4 per cohort). (A) Graphical representation of the study design
(m.o., months old). (B) GAA enzymatic activity measured in plasma at 1, 3, 6, and 9months postinjection. (C) GAA enzymatic activity in heart, diaphragm, and tricepsmuscles,
reported as percentage of PBS-Gaa+/+ activity. (D) Glycogen content in heart, diaphragm, and triceps muscles, reported as percentage of PBS-Gaa/ glycogen. (E)
Hypertrophy of cardiac muscle, reported as heart weight percentage of body mass. (F) Grip-test analysis reported as percentage of PBS-Gaa+/+ muscle strength. (G) Tidal
volume measured by whole-body plethysmography. Statistical analyses: (B, E, and G) one-way ANOVA with Tukey’s post hoc. **p < 0.01; (C and D) two-way ANOVA with
Tukey’s post hoc (treatment, tissue). *p < 0.05; **p < 0.01; ****p < 0.0001; (F) two-way ANOVA with Tukey’s post hoc (treatment, time). #p < 0.05; ** or ##p < 0.01; ###p <
0.001; **** or ####p < 0.0001. In all graphs, error bars represent the standard deviation of the mean.
Molecular Therapy
2060 Molecular Therapy Vol. 28 No 9 September 2020
Figure 3. Hepatic Expression of secGAA Partially Normalizes Glycogen Content in the Central Nervous System
(A–E) 9-month-old mice were injected with an AAV8-secGAA (secGAA-Gaa/) vector at a dose of 2  1012 vg/kg. Gaa+/+ (PBS-Gaa+/+) and Gaa/ (PBS-Gaa/) mice
injected with PBS served as controls in the study. Animals were followed for 9 months after treatment (n = 3/4 per cohort). (A) GAA enzymatic activity in brain and spinal cord
reported as percentage of PBS-Gaa+/+ activity. (B) Glycogen content in brain and spinal cord reported as percentage of PBS-Gaa/ glycogen. (C and D) Western blot
analysis of brain (C) and spinal cord (D) lysates, 9 months after treatment using anti-GAA monoclonal antibody. An anti-tubulin antibody was used as a loading control. (E)
Representative images of periodic acid-Schiff (PAS) staining of brain sections. Insets represent the caudate putamen (striatum) region of the brain. Statistical analysis: (A and
B) two-way ANOVA with Tukey’s post hoc (treatment, tissue). *p < 0.05; ***p < 0.001; ****p < 0.0001. In all graphs, error bars represent the standard deviation of the mean.
www.moleculartherapy.orgin the three cohorts (PBS-Gaa+/+, PBS-Gaa/, and secGAA-Gaa/)
(Figure S8). Interestingly, at the transcriptomics levels, approximately
75% of genes involved in fibrosis and fibrogenesis, which were dysre-
gulated in PBS-Gaa+/+ mice, were FR or PR upon AAV-secGAA treat-
ment (Figure S8). Together, these results highlight a significant
amelioration of PD at the transcriptional level.AAV8-secGAA Liver Gene Transfer Partially Re-establishes
Mitochondria Homeostasis in 18-Month-Old Gaa–/– Mice
Deeper analysis of mechanistic differences was performed using the
transcriptome data from skeletal muscle of Gaa/ compared to
Gaa+/+ mice to better evaluate the bioenergetics defects. Upstream
regulator analysis (IPA) identified various TFs involved in oxidativeMolecular Therapy Vol. 28 No 9 September 2020 2061
Figure 4. AAV-Mediated secGAA Expression Restores Histology and Partially Reverses Autophagy Block in Muscle
(A–E) 9-month-old mice were injected with an AAV8-secGAA (secGAA-Gaa/) vector at a dose of 2  1012 vg/kg. Gaa+/+ (PBS-Gaa+/+) and Gaa/ (PBS-Gaa/) mice
injected with PBS served as controls in the study. Animals were followed for 9months after treatment (n = 3/4 per cohort). (A) Representative images of hematoxylin and eosin
(H&E) staining of diaphragm, heart, and triceps. Scale bar, 10 mm. (B) Western blot analysis of triceps lysates using anti-p62/sequestosome-1 (SQSTM1) monoclonal
antibody. An anti-GAPDH antibody was used as a loading control. (C) Western blot analysis of triceps lysates using anti-Lamp1 polyclonal and anti-Beclin1 polyclonal
antibodies. An anti-GAPDH antibody was used as a loading control. (D) Western blot analysis of triceps lysates using anti-LC3b monoclonal antibody. An anti-GAPDH
antibody was used as a loading control. (E) Quantification of p62 levels normalized to GAPDH levels. (F) Quantification of Lamp1 levels normalized to GAPDH levels. (G)
Quantification of Beclin1 levels normalized to GAPDH levels. (H) Quantification of LC3b-I levels normalized to GAPDH levels. (I) Electron microscopy analysis of tibialis anterior.
Arrows indicate enlarged lysosomes. Scale bars, 2 mm. (J) Quantification of lysosome length from the sections in electron microscopy. Statistical analyses: (E–H) one-way
ANOVA with Tukey’s post hoc. *p < 0.05; **p < 0.01. (J) unpaired t test. *p < 0.0001. In all graphs, error bars represent the standard deviation of the mean.
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Figure 5. AAV8-secGAA Restores Physiological
Mitochondrial Content in Skeletal Muscle
(A–G) 9-month-old mice were injected with an AAV8-sec-
GAA (secGAA-Gaa/) vector at a dose of 2  1012 vg/kg.
Gaa+/+ (PBS-Gaa+/+) and Gaa/ (PBS-Gaa/) mice in-
jected with PBS served as controls in the study. Animals
were followed for 9 months after treatment (n = 3/4 per
cohort). (A) Mitochondria analysis in tibialis anterior using
electron microscopy. Arrows indicate regions with accu-
mulatedmitochondria. Squares indicate zoomed areas that
are presented in the lower panels. Scale bars, 2 mm. (B)
Western blot analysis of triceps lysates using anti-CoxIV
monoclonal antibody. An anti-GAPDH antibody was used
as a loading control. (C) Quantification of CoxIV levels from
the corresponding western blots shown in (B). (D) Western
blot analysis of triceps using anti-ATP-b monoclonal anti-
body. An anti-GAPDH antibody was used as a loading
control. (E) Quantification of ATP-b levels from the corre-
sponding western blots shown in (D). (F) Western blot
analysis of triceps using anti-SDHA monoclonal antibody.
An anti-GAPDH antibody was used as a loading control. (G)
Quantification of SDHA levels from the corresponding
western blots shown in (F). Statistical analysis: (C, E, and G)
one-way ANOVA with Tukey’s post hoc. ***p < 0.001;
****p < 0.0001. In all graphs, error bars represent the
standard deviation of the mean.
www.moleculartherapy.orgstress, which were associated to genes with altered expression in PBS-
Gaa/ mice relative to PBS-Gaa+/+ mice, such as hypoxia-inducible
factor 1 alpha (Hif1a), nuclear factor erythroid 2-like 2 (NFE2L2; also
known as Nrf2), and mitochondrial homeostasis, such as peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PPARGC1a), peroxisome proliferator-activated receptor gamma co-
activator 1 beta (PPARGC1b), and sirtuin1 (Sirt1), which were en-Moleculariched in PBS-Gaa/mice (Figure 7A). Interest-
ingly, PPARGC1a and PPARGC1b, central
players of mitochondrial biogenesis,47 were pre-
dicted as inhibited (negative Z score) in Gaa/
mice (Figure 7A). This was consistent with the
high mitochondrial content detected in skeletal
muscle (Figure 5), linked to defective mitophagy
and consequent inhibition of the mitochondrial
biogenesis machinery as a compensatory mecha-
nism.48 Given that the oxidative stress-related
TFs (including Nrf2 and Hif1a) were predicted
to be more active in PBS-Gaa/ than PBS-
Gaa+/+ (with a positive Z score), we decided to
asses global reactive oxygen species (ROS) pro-
duction in skeletal muscle. We observed slightly
elevated amounts of ROS in PBS-Gaa/ ani-
mals, which where normalized upon treatment
with secGAA (Figure 7B).
To test whether the correction of mitochondrial
content in skeletal muscle of AAV-treatedGaa/ mice was accompanied by a recovery of mitochondrial func-
tion, we performed a western blot analysis of key players inmitochon-
drial homeostasis in skeletal muscle. We looked at the “energy sensor”
serine/threonine kinase AMP-activated protein kinase (AMPK) com-
plex,49 based on the fact that AMPK signaling was significantly en-
riched in Gaa/ mice compared to Gaa+/+ mice and that genes regu-
lated by AMPK signaling were rescued in AAV8-secGAA-treatedr Therapy Vol. 28 No 9 September 2020 2063
Figure 6. AAV Liver Gene Therapy Largely Normalizes Transcriptome in Muscle
(A and B) 9-month-old mice were injected with an AAV8-secGAA (secGAA-Gaa/) vector at a dose of 2 1012 vg/kg. Gaa+/+ (PBS-Gaa+/+) and Gaa/ (PBS-Gaa/) mice,
injected with PBS, served as controls in the study. Animals were followed for 9 months after treatment (n = 3/4 per cohort). (A) Gene expression in quadriceps muscle tissue
from PBS-Gaa/, PBS-Gaa+/+, and secGAA-Gaa/mice was analyzed by RNA sequencing. The expression profiles of 2,864 genes, detected as differentially expressed in
any of the three possible pairwise contrasts (Figure S4B), were assigned to clusters using k-means. Threemetaclusters, containing genes in which their expression levels had
been fully rescued (FR; 23.3%, 666 genes), partially rescued (PR; 51.3%, 1,470 genes), or not rescued (NR; 25.4%, 728 genes) by the expression of secGAA in the Gaa/
background, were defined by combining gene clusters with complementary expression profiles. Normalized expression counts, averaged for each condition and scaled for
each gene, are represented on the y axis. Gray lines represent the expression profile of individual genes. Black lines represent average expression profiles for each of the
combined clusters. (B) Significant associations in 9 of total 41 canonical pathways were found for the three metacluster gene lists (FR, PR, and NR) after Ingenuity Pathway
Analysis (IPA) enrichment analyses. Bar plots represent Fisher’s test p values for nine of the pathways and the threemetaclusters. Red lines indicate the significance threshold
(p < 0.05). Results for the remaining 33 pathways are presented in Figure S6.
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Figure 7. AAV8-secGAA Administration Partially
Normalizes Mitochondrial Stress Signaling in
Skeletal Muscle
(A) Significant associations to 257 upstream transcrip-
tional regulators were found for the set of 2,802 genes
detected as differentially expressed in the comparison of
PBS-Gaa/ versus PBS-Gaa+/+ after IPA enrichment
analyses. The circular plot represents a subset of 16
regulators involved in metabolic processes and a selec-
tion of their connected functions retrieved from IPA’s
knowledge base with the “grow” function. Circular crown
sectors, representing transcriptional regulators, are
colored according to activation Z score. Red and blue
colors indicate a higher activation state in PBS-Gaa/ or
PBS-Gaa+/+ mice, respectively. (B–D) 9-month-old mice
were injected with an AAV8-secGAA (secGAA-Gaa/)
vector at a dose of 2  1012 vg/kg. Gaa+/+ (PBS-Gaa+/+)
and Gaa/ (PBS-Gaa/) mice injected with PBS served
as controls in the study. Animals were followed for
9 months after treatment (n = 3/4 per cohort). (B) ROS
production measured in snap-frozen tissues by EPR
spectroscopy. (C) Western blot analysis of triceps lysates
using monoclonal antibody anti-AMPK. An anti-GAPDH
antibody was used as a loading control. (D) Quantification
of AMPK levels normalized to GAPDH levels from the
corresponding western blot shown in (C). Statistical
analysis: one-way ANOVA with Tukey’s post hoc. **p <
0.01. In all graphs, error bars represent the standard
deviation of the mean.
www.moleculartherapy.organimals (Figure 6B). Interestingly, we observed increased levels,
which were normalized levels upon AAV8-secGAA treatment, of
AMPK in PBS-treated Gaa/ mice (Figures 7C and 7D). In sum-
mary, transcriptomic data and biochemical analysis suggest that
long-term exposure to secGAA, following hepatic gene transfer, re-
sults in partial normalization of mitochondrial homeostasis in skeletal
muscle of Gaa/ mice with advanced disease.
DISCUSSION
PD is a progressive neuromuscular disease caused by accumulation of
lysosomal glycogen, which results in tissue disruption, autophagy
block, andmetabolic impairments.1 Introduction of ERT with rhGAA
represented amajor advance in the treatment of PD, being a lifesaving
treatment for infantile patients3,50,51 and providing benefit to the
adult Pompe population.11,52,53 In vivo gene delivery with AAV vec-
tors is a promising alternative to ERT for PD, owing to the promising
results in preclinical models of the disease26,54,55 and the excellent
safety and efficacy profile in human trials for a variety of dis-
eases.14,16,20,56,57 We previously demonstrated the full rescue of PD
in 4-month-old Gaa/ mice using a secretable form of the GAA
enzyme expressed in hepatocytes via AAV vectors.26 Here, we further
defined the therapeutic potential of this approach by comparing the
long-term effect of low vector doses of AAV8 vectors expressing sec-
retable GAA or its native counterpart in Gaa/ mice treated at
4 months of age. Despite the small increase in GAA activity, detect-
able in tissues of animals treated with secretable GAA, survival data
clearly demonstrate that, at 5  1011 vg/kg, native GAA is unableto provide any therapeutic benefit, whereas Gaa/ mice treated
with secretable GAA present a lifespan undistinguishable from that
of wild-type littermates. These results are of fundamental importance
in the prospective of translating these results to the clinic, as the use of
transgenes with enhanced bioavailability, like secretable GAA, could
potentially provide superior therapeutic benefit to patients, while
reducing the AAV doses administered. Importantly, the use of trans-
genes with an improved therapeutic index in the context of hemophil-
ia B gene-therapy trials allowed a decrease in the therapeutic vector
dose, thus reducing capsid immune-mediated toxicities16 and poten-
tially lowering manufacturing requirements. Future side-by-side
studies of gene transfer of secretable GAA with the current standard
of care for PD1 will help highlight differences in pharmacokinetics
and bioavailability between gene therapy and ERT.
An open question about ERT, which also concerns all novel therapies
for PD, is whether providing a source of GAA enzyme could reverse
an already-established disease phenotype. Experience with ERT in
IOPD patients shows clear beneficial effects, including the resolution
of hypertrophic cardiomyopathy, amelioration of muscle functions,
and, importantly, survival.3,50,51 However, in this patient population,
early intervention is crucial for a positive treatment outcome,12 sug-
gesting that the effects of glycogen accumulation are poorly reversible
with ERT. Similarly, LOPD patients receiving ERT in the long term
tend to achieve, at best, stable muscle and respiratory functions,11,52,53
possibly due to the fact that ERT is started when patients become
symptomatic, thus with relatively advanced disease progression.58Molecular Therapy Vol. 28 No 9 September 2020 2065
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cle has also been demonstrated to hamper the trafficking of rhGAA in
the context of ERT.8,29
In the context of gene transfer, two studies attempted to correct PD in
Gaa/ mice with an advanced pathology. A first study described 10-
month-old Gaa/ mice treated with an AAV vector expressing the
GAA transgene in the liver.27 Despite the high vector dose used
(1  1012/mouse), 6 months after treatment, the animals showed
only partial glycogen clearance in skeletal muscle and no improve-
ments of muscle function.27 In a second study, 12-month-old Gaa/
mice received an AAV vector expressing a GAA transgene carrying a
heterologous signal peptide to enhance secretion from hepatocytes.28
Also, in this case, AAV-treated mice exhibited incomplete reduction
of glycogen in muscle.28 Additional published data in Gaa/ mice
with advanced phenotype show lack of correction of glycogen accu-
mulation with muscle-directed expression of GAA.59 Results pre-
sented here clearly show that hepatic expression of secretable GAA re-
sults in clearance of glycogen frommultiple tissues, including a partial
clearance in CNS, and restoration of muscle function to wild-type
levels in Gaa/ mice with advanced pathology. Although this is
somewhat in contrast with published findings,27,28,59 the higher
bioavailability of secretable GAA compared with the native form of
the enzyme or with enzymes carrying heterologous signal peptides26
could explain our findings. Alternatively, the difference in time of
follow-up and age of inclusion of the animals in the study, as well
as genetic background of the Gaa/ colonies used in the study,24,25,60
could explain the observed differences across studies. The fact that an-
imals presented a clear, severe phenotype at the time of treatment,
both in terms of glycogen accumulation and muscle strength, would
argue that hepatic expression of secretable GAA can efficiently
reverse an advanced disease phenotype in Gaa/ mice. Transcrip-
tomics analysis of genes involved in muscle regeneration and remod-
eling observed in our study further supports our findings, although
similar studies in the context of gene therapy trials will be necessary
to elucidate the effects of secretable GAA expression on human mus-
cle plasticity. Morphological changes observed in skeletal muscle
of Pompe patients, followed by magnetic resonance imaging
(MRI),61,62 show gradual replacement of skeletal muscle mass with
fat tissue, a hallmark of muscle degeneration.63 This phenomenon
has not been documented in Gaa/ mice, which could indicate
that the animal model fails to fully recapitulate the human
condition when it comes to muscle pathophysiology. Results in our
study show that, at 18 months of age, untreated Gaa/ mice show
a marked decrease of skeletal muscle mass, and secretable GAA
treatment appears to restore both skeletal muscle and body weight
to wild-type levels.
Another possible shortcoming of the current study is the small num-
ber of animals per cohort. Whereas a larger study could address this
point and help us to understand the reversibility of more variable end-
points of therapeutic efficacy, like those reflecting respiratory func-
tion,34,64,65 limited, long-term survival of untreated Gaa/ mice26
limits the ability to conduct larger studies with aged Pompe mice.2066 Molecular Therapy Vol. 28 No 9 September 2020Nevertheless, statistical analysis and correlation of multiple endpoints
at the biochemical, functional and morphological level and the
changes in the transcriptional signature of skeletal muscle support
the robustness of the current findings on the reversibility of the
advanced Pompe phenotype in mice.
Consistent with previous findings in PD26 and other lysosomal stor-
age disorders (LSDs),66 mice treated with secretable GAA showed a
significant glycogen reduction in the CNS, although a full evaluation
of CNS rescue, previously reported by our lab,26 was not presented in
the current study. Themechanism underlying transport of GAA from
the systematic circulation to the CNS is currently unknown and could
involve transcytosis, transport via exosomes,67 or lysosomal exocy-
tosis at neuromuscular junctions.68 Although encouraging, these re-
sults suggest that high plasma levels of GAA derived from the hepatic
expression of secGAA are likely to be needed to fully correct the CNS
manifestations characteristic of IOPD.34,69 Alternatively, direct tar-
geting of neurons has also been explored,70 although this strategy
achieved full correction of CNS glycogen accumulation with little ef-
fect on peripheral tissues and muscle function. Notably, a GAA-ex-
pressing vector based on the recently developed AAV-PHP.B sero-
type71 delivered at high doses (5  1012 vg/kg) completely cleared
heart and brain glycogen in Pompe mice, while reducing glycogen
content in quadriceps and gastrocnemius.72
Lysosomal defects have been linked to severe autophagy impairment in
skeletal muscle of both Pompe patients and Gaa/ mice.29,36 In addi-
tion, studies in primary cell cultures and muscle tissue from Gaa/
mice show secondary defects inmitochondria andmitophagy,30 consis-
tentwith recentfindings on the linkbetween autophagy block andmito-
chondria impairment in juvenile Gaa/mice.31 Clearance of defective
mitochondria via mitophagy is essential to maintain a healthy mito-
chondrial network, whereas accumulation of dysfunctional mitochon-
dria can have detrimental consequences in various diseases, including
LSDs.73 Here, we showed that liver expression of secretable GAA
normalized both autophagy and mitophagy, as documented by EM
and western blot analyses, with normalization of lysosomal length
and markers of autophagy, such as p62, Lamp1, and LC3b, as well as
normalization of mitochondria content and improvements in mito-
chondria metabolism in skeletal muscle, as suggested by changes in
AMPK levels. Impairedmitophagy at 18months of age resulted in accu-
mulation of mitochondria andmodestly increased levels of ROS, which
were normalized by clearance of mitochondria. At the transcriptomics
level, untreated Gaa/ showed profound alterations of mitochondrial
biogenesis and upregulation of inflammatory pathways in skeletalmus-
cle, similar to findings in other LSDs.74 Large transcriptional alterations
were observed in the muscle of untreated Pompe mice at the end of the
observational study—18 months. Liver expression of secretable GAA
resulted in either full or partial rescue of the expression pattern of about
two-thirds of the genes studied. Signaling pathway analysis confirmed
partial rescue of the alterations observed in Pompe mice. Those alter-
ations were possibly related to the deep modifications of the muscle
physiology, and their partial rescue after gene transfer was likely ex-
pected. As Pompe patients have access to ERT, it is conceivable that
www.moleculartherapy.orgthemuscle of humanswould present a somewhat less altered expression
pattern.Work by Koeberl and colleagues75 reported a short list of genes
for which their expression level was normalized after clenbuterol treat-
ment in Pompe patients. Interestingly, NFE2 is one of the genes with
normalized expression, showing the importance of our findings on
normalization of oxidative stress-related transcriptomic changes and
ROS levels.75
Characterization of satellite cells in muscle biopsies from both IOPD
and LOPD patients suggests that satellite cells found inmuscle are not
altered in number but are less functional.76 Two independent studies
reported that the Gaa/ mouse has functionally normal satellite
cells; however, they are not capable of repairing disease damage, prob-
ably due to an activation signal defect.33,42 Here, we observed partial
rescue of genes related to muscle plasticity after gene transfer,
although the activation state of satellite cells in old mice may be
affected by age-related changes unrelated to PD.77 Additional studies
in Pompe mice and in PD patients will be required to further under-
stand differences in plasticity of the muscle across species and in
particular, whether gene transfer with secretable GAA will result in
rescue of PD in older patients.
Further work is also needed to assess the therapeutic potential of our
approach in IOPD patients. Because of the nonintegrative nature of
AAV vectors, treatment of newborn IOPD patients with liver-ex-
pressed secretable GAA might result in transient expression of the
donated transgene. This would require the readministration of the
therapeutic vector78 to counteract vector genome dilution and loss
of transgene expression due to liver growth.79
In summary, this work confirms the superior therapeutic efficacy of
secretable GAA compared to the native form of the enzyme. It also
demonstrates that gene transfer with secretable GAA drives efficient
rescue of the advanced Pompe phenotype in Gaa/ mice and in
particular, has a profound impact on the restoration of autophagy,
mitophagy, and overall bioenergetic and inflammatory homeostasis
of muscle. Future translation of the therapeutic modality based on
secretable GAA to the clinic will help address similar mechanistic
questions on the reversibility of the Pompe phenotype in humans.MATERIALS AND METHODS
GAA Expression Cassettes and AAV Vectors
The GAA transgene expression cassettes containing the codon-opti-
mized coding sequence encoding for the native and secretable forms
of human GAA were previously described.26
AAV vectors used in this study were produced using an adenovirus-
free transient transfection method, as described earlier.80 Titers of
AAV vector stocks were determined using quantitative real-time
PCR and confirmed by SDS-PAGE, followed by SYPRO Ruby protein
gel stain and band quantification using ImageJ software. All vector
preparations used in the studies were quantified side by side at least
3 times before use.In Vivo Studies
Mouse studies were performed according to the French and European
legislation on animal care and experimentation (2010/63/EU) and
approved by the local Institutional Ethical Board (protocol number
2015-008).
The Gaa/ mice were purchased from Jackson Laboratory (B6; 129-
Gaatm1Rabn/J, stock number 004154, 6neo). This mouse model was
originally generated by Raben et al.24 Gaa+/+ are derived from the
same colony and breed separately.
For the comparative analysis of GAAco with secGAA, AAV8-
GAAco or AAV8-secGAA26 was administered intravenously to
4-month-old male mice. Gaa/ mice were treated at a vector
dose of 5  1011 vg/kg and followed for 10 months (n = 7 per treat-
ment group). Gaa/ and Gaa+/+ mice were injected with PBS and
used as controls (n = 8 per group).
For the treatment of mice at advanced stages of PD, an AAV8-sec-
GAA vector26 was administered intravenously via the tail vein to
9-month-old male mice. Gaa/ mice were treated at a vector dose
of 2  1012 vg/kg and followed for 9 months (n = 3/4 per treatment
group). Age-matched Gaa/ and Gaa+/+ mice were injected with
PBS and used as controls. All of the animals were perfused at the
time of sacrifice.
Vector Genome Copy Number Analysis
Vector genome copy number was determined using quantitative
real-time PCR, as previously described.26 The PCR primers used in
the reaction were located on the human alpha-1 antitrypsin promoter
sequence within the expression cassette: forward primer, 50-GGC
GGGCGACTCAGATC-30; reverse primer 50-GGGAGGCTGCTGG
TGAATATT-30.
Measurement of GAA Activity and Glycogen Content
GAA activity was measured as previously described.81 Briefly, 10 mL
of sample, either tissue homogenate or plasma, was incubated for 1 h
at 37C with 20 mL of 4-methylumbelliferyl a-d-glucopyranoside
(3 mM), diluted in acetate buffer solution (pH 4.65) (Sigma-Aldrich).
The reaction was stopped using the carbonate solution, and the fluo-
rescence (lex 360 nm/lem 449 nm) was read with an EnSpire alpha
plate reader (PerkinElmer, Waltham, MA). A standard curve was
prepared using 4-methylumbelliferone, diluted in 0.5 M of carbonate
solution (pH 10.5).
Glycogen content was measured indirectly in tissue homogenates
as the glucose released after total digestion withAspergillus niger amy-
loglucosidase (Sigma-Aldrich, St. Louis, MO, USA). Samples were
incubated for 5 min at 95C and then cooled at 4C; 25 mL of amylo-
glucosidase diluted 1:50 in 0.1 M potassium acetate (pH 5.5) was then
added to each sample. A control reaction without amyloglucosidase
was prepared for each sample. Both sample and control reactions
were incubated at 37C for 90 min. The reaction was stopped by incu-
bating samples for 5 min at 95C. The glucose released wasMolecular Therapy Vol. 28 No 9 September 2020 2067
Molecular Therapydetermined using a glucose assay kit (Sigma-Aldrich, St. Louis, MO,
USA) and by measuring resulting absorbance at the EnSpire alpha
plate reader (PerkinElmer, Waltham, MA, USA) at 540 nm.Western Blot Analyses
Mouse tissues were mechanically homogenate in H2O using lysing
matrix tubes (MP Biomedicals). Protein concentration was deter-
mined using the bicinchoninic acid (BCA) Protein Assay Kit
(Thermo Fisher Scientific, Waltham, MA, USA).
SDS-PAGE was performed in a 4%–15% gradient polyacrylamide gel.
After transfer, the membrane was blocked with Odyssey buffer (LI-
COR Biosciences, Lincoln, NE, USA) and incubated with an anti-
GAA antibody (rabbit monoclonal; Abcam, Cambridge, MA, USA),
anti-p62 (mouse monoclonal; Abcam, Cambridge, MA, USA), anti-
LAMP1 (rabbit polyclonal; Abcam, Cambridge, MA, USA), anti-Be-
clin1 (rabbit polyclonal; Abcam, Cambridge, MA, USA), anti-LC3B
(rabbit polyclonal; Novus Biologicals), anti-tubulin (mouse mono-
clonal; Sigma), anti-actin (rabbit polyclonal; Sigma), anti-glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (rabbit polyclonal;
Thermo Fisher Scientific), anti-AMPK (rabbit polyclonal; Cell
Signaling Technology), anti-CoxIV (rabbit polyclonal; Abcam, Cam-
bridge, MA, USA), anti-ATP-b (mouse monoclonal; Abcam, Cam-
bridge, MA, USA), and anti-SDHA (mouse monoclonal; Invitrogen)
. The membrane was washed and incubated with the appropriate sec-
ondary antibody (LI-COR Biosciences), conjugated with fluorescent
probes with extended linear range, and visualized by the Odyssey im-
aging system (LI-COR Biosciences), which allows identification and
exclusion of saturated signals during band quantification.Histological Evaluation
For histology, immediately after euthanasia, heart, triceps brachii,
diaphragm, and brain were snap frozen in isopentane (160C), pre-
viously chilled in liquid nitrogen. Serial 8 mm cross-sections were cut
in a Leica CM3050 S cryostat (Leica Biosystems). To minimize sam-
pling error, 3 sections of each specimen were obtained and stained
with H&E, sirius red, and PAS, according to standard procedures.Electron Microscopy Analyses
Muscle samples were fixed with 2.5% of glutaraldehyde (Sigma-Al-
drich) in 0.1 M PHEM (pH 7.2). Postfixation was done with 1%
osmium tetroxide (Merck) and 1.5% ferrocyanide (Sigma-Aldrich)
in 0.1 M HEPES. After dehydration by a graded series of ethanol,
the tissue samples were infiltrated with epoxy resin. Polymerized resin
blocks were thin sectioned longitudinally using a Leica UC 7 micro-
tome (Leica Microsystems).The 70-nm sections were collected on
Formvar-coated slot grids (Electron Microscopy Sciences [EMS])
and were contrasted with 4% uranyl acetate and Reynolds lead citrate.
Stained sections were observed with a Tecnai spirit Field Electron and
Ion (FEI) operated at 120 kV. Images were acquired with FEI Eagle
digital camera. Quantification of lysosome length was performed us-
ing ImageJ software.2068 Molecular Therapy Vol. 28 No 9 September 2020Functional Assessment
Respiratory function during quiet breathing was evaluated as already
reported.26,34 Briefly, a flow-through (0.5-L/min) plethysmograph
(Emka Technologies, Paris, France) was used to measure the breath-
ing pattern in treated Gaa/ mice and untreated Gaa/ and wild-
type littermates. Before the assessment, the instrument was calibrated
with known airflow and pressure signals for optimal data collection.
Signals were analyzed by using IOX2 software (Emka Technologies).
Tidal volume was evaluated over a period of 5 min. Animals were al-
lowed for acclimation into the plethysmograph chamber before
testing. During both acclimation and data acquirement, mice were
breathing normoxic air (21% O2, 79% N2).
Grip strength was measured, as already reported, by the TREAT-
NMD Network (https://treat-nmd.org). The test was performed on
AAV-treated Gaa/mice and untreated Gaa/ and wild-type litter-
mates. With the use of a grip-strength meter (Columbus Instruments,
San Diego, CA), three independent measurements of the four limbs’
strength were calculated. Mean values of the grip strength were
reported.
Electron Paramagnetic Resonance (EPR) Spectroscopy
Free radical production was measured by EPR spectroscopy using 1-
hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl pyrrolidine hydro-
chloride (CMH; Noxygen, Elzach, Germany) as a spin probe. In brief,
muscles were frozen in liquid nitrogen and kept at80C until assay.
Tissues were weighed and homogenized in Krebs-HEPES buffer (pH
7.4). Then, samples were incubated in Krebs-HEPES buffer contain-
ing 5 mM diethyldithiocarbamic acid silver salt (DETC), 25 mM de-
feroxamine (DF), and 50 mM of CMH in 24-well plates at 37C.
Blank wells without tissue were prepared in parallel. After a 60-min
incubation, samples were immediately frozen in liquid nitrogen to
stop the reaction. Oxidized CMH spectra were recorded with a Min-
iScope MS-200 (Magnettech, Berlin). Acquisition EPR parameters
were the following: Bo-field 3325.96 G; microwave power 1 mW;
modulation amplitude 5 G; sweep time 60 s. Spectra intensity was ex-
pressed in arbitrary units, normalized per milligram of protein.
RNA Isolation and Transcriptome Profiling
The RNAs were isolated from snap-frozen quadriceps tissues pre-
served at 80C. Samples were initially homogenized in Trizol, and
total RNA was column purified by PureLink RNA Mini Kit (Invitro-
gen). Next-generation sequencing (NGS) experiments were per-
formed in the Genomics Unit of the Centro Nacional de Investiga-
ciones Cardiovasculares (CNIC; Madrid, Spain). 200 ng of total
RNA was used to generate barcoded RNA sequencing (RNA-seq) li-
braries using the NEBNext Ultra RNA Library Prep Kit (New En-
gland Biolabs). Briefly, poly A+ RNA was purified using poly-T
oligo-attached magnetic beads, followed by fragmentation, and then
first and second cDNA strand synthesis. Next, cDNA 30 ends were ad-
enylated, and the adapters were ligated followed by PCR library
amplification. Finally, the size of the libraries was checked using the
Agilent 2100 Bioanalyzer DNA 1000 chip, and their concentration
was determined using the Qubit fluorometer (Life Technologies).
www.moleculartherapy.orgLibraries were sequenced on a HiSeq 2500 (Illumina) to generate 60
bases of single reads. FastQ files for each sample were obtained using
CASAVA version (v.)1.8 software (Illumina). Sequencing data dis-
cussed here have been deposited in NCBI’s Gene Expression
Omnibus and accessible through GEO: GSE150935.
Bioinformatics Analysis of RNA Sequencing Data
RNA-seq data analysis was performed by the Bioinformatics Unit of
CNIC (Madrid, Spain). Sequencing reads were processed with a pipe-
line that used FastQC to evaluate their quality (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/; developed by the
Barbraham Institute) and cutadapt to trim sequencing reads, elimi-
nating Illumina adaptor remains, and to discard reads that were
shorter than 30 bp. Resulting reads were mapped against mouse tran-
scriptome GRCm38.91, and gene-expression levels were estimated
with RNA-Seq by Expectation-Maximization (RSEM).82 Around
91% of the reads from any sample participated in at least one reported
alignment. Expression count matrices were then processed with an
analysis pipeline that used Bioconductor package linear models for
microarray data (limma) for normalization (using the trimmed
mean of M-values normalization [TMM] method) and differential
expression testing.83 Changes in gene expression were considered
significant if associated to a Benjamini and Hochberg adjusted
p value < 0.05.
The expression profiles of 2,864 genes detected as differentially ex-
pressed in any of the three performed contrasts (Figure S4C) were
clustered using k-means with n = 6. Clusters with complementary
expression profiles were combined to define three metaclusters (Fig-
ure 7A). Each metacluster contained genes with expression levels that
had been FR, PR, or NR in animals receiving the AAV8-secGAA
vector.
Differentially expressed and metacluster gene collections were pro-
cessed with IPA (QIAGEN) to identify associations with canonical
pathways, diseases and biofunctions, and upstream transcriptional
regulators. Functional associations provided by IPA are character-
ized by two parameters: p values to describe enrichment test signif-
icance and Z scores to indicate predicted activation state. Enrich-
ments were considered significant if associated to a p value < 0.05.
The calculation of Z score for a given pathway, or regulator, is based
on the fold-change value of associated genes and can only be
applied, by definition, to pairwise contrast results. Positive and
negative Z scores suggest higher activity in the first or the second
condition being compared, respectively. Absolute Z score (abs(Z
score)) values higher than 2 are considered relevant. Circular plots,
representing the association between enriched transcriptional regu-
lators and functional terms, were produced with the GOplot
package.84
Statistical Analysis
All of the data shown in the present manuscript are reported as
mean ± standard deviation. The number of sampled units (n),
upon which we reported statistics, is the single mouse for the in vivoexperiments (one mouse is n = 1). GraphPad Prism 7 software
(GraphPad Software) was used for statistical analyses. p values
<0.05 were considered significant. For all of the datasets, data were
analyzed by parametric tests, alpha = 0.05 (one-way and two-way
ANOVA with Tukey’s post hoc correction and multiple t tests with
Sidak-Bonferroni post hoc correction). The survival of mice was
compared by Kaplan-Meier log rank test. The statistical analysis per-
formed for each dataset is indicated in the figure legends.
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